Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Combinatorial BCG.AstaX vaccine inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of NRF2, TLR2, MHCII, IL-12, STAT1/2, IRF9/3, IFITM-3/2/1, Interferon-alpha/beta/gamma/lamda, AMPs, while decreasing the expression of ACE2, Furin, SR-B1, HIF-1alpha and NRP-1 (Neuropilin) and others 23/December/2020, 12.50 pm 23/December/2020, 12.50 pm

LncRNA-based regenerative cardiovascular therapy: LncRNA SNHG14 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 18/December/2020, 9.55 pm
December 18, 2020
Regenerative cardiovascular therapy: ELK1 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 1/January/2021, 11.49 pm
January 1, 2021
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33), by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Combinatorial BCG.AstaX vaccine inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of NRF2, TLR2, MHCII, IL-12, STAT1/2, IRF9/3, IFITM-3/2/1, Interferon-alpha/beta/gamma/lamda, AMPs, while decreasing the expression of ACE2, Furin, SR-B1, HIF-1alpha and NRP-1 (Neuropilin) and others 23/December/2020, 12.50 pm


What is known?

Prof. Stephen Elledgeresearch team has showed thatinterferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that combinatorial Bacillus Calmette Guerin (BCG) vaccine-based therapy, with detailed mechanistic insights, for COVID-19 and other infectious diseases. Combinatorial BCG.AstaX vaccine, comprising BCG vaccine and Astaxanthin, by increasing the expression of its target genes, it may increase the expression of NRF2, TLR2, MHCII, IL-12, STAT1/2, IRF9/3, Interferon-alpha/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM 3/2/1, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides (LL37) and others (Fig.1), while decreasing the expression of ACE2, Furin, SR-B1, HIF-1alpha and NRP-1 (Neuropilin) and others. Thereby, it may: (1) inhibit the replication of  SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing “Combinatorial BCG.AstaX vaccine, either alone or in combination with other drugs, can be used to prevent/treat/protect against infections caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial,  Sindbis, and SFV viruses (Figure 2).

Figure 1 Mechanistic insight into how a combinatorial BCG.Axtax vaccine protects against a number of infectious diseases. A pharmaceutical mixture encompassing BCG and Astaxanthin vaccine protects against SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses production through induction of its target genes, such as antiviral Proteins STAT1/2, IRF9/3, IFITM3/1, Interferon-alpha/beta/gamma/lamda, Interferon-stimulated gene 15, Mx2 and others
Figure 2 What constitutes combinatorial BCG.Astax vaccine; and how it protects against several infectious diseases.
Figure 3.  A combinatorial BCG.AstaX vaccine can function as a broad-spectrum anti-infective agent against a number of infectious diseases.
Figure 4.  Combinatorial BCG.Astax vaccine can prevent/treat/protect against SARS-COV-2.
Figure 5.  A pharmacological formulation encompassing BCG vaccine and Astaxanthin as COVID-19 vaccine. GBMD (genomediscovery.org) is looking for collaborators who wish to take it to the next stage.

Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How combinatorial BCG.AstaX vaccine increases the expression of antiviral Protein IFITM3/2/1, Interferon-stimulated gene 15, & Mx2, while decreasing the expression of ACE2, Furin, SR-B1, HIF-1alpha and NRP-1 (Neuropilin)

Type: Research cooperation

For more details on research cooperation, you may reach us at drboomi@genomediscovery.org or admin@genomediscovery.org


References: 

CitationBoominathan L, Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Combinatorial BCG.AstaX vaccine inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of NRF2, TLR2, MHCII, IL-12, STAT1/2, IRF9/3, IFITM-3/2/1, Interferon-alpha/beta/gamma/lamda, AMPs, while decreasing the expression of ACE2, Furin, SR-B1, HIF-1alpha and NRP-1 (Neuropilin) and others 23/December/2020, 12.50 pm

Courtesy: When you cite drop us a line at info@genomediscovery.org, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.